The Myeloma Drug Tracker shows where drugs are in the clinical trial pathway as potential treatments for myeloma. Available drugs are ones which have already been licensed for use in myeloma.
Using the filters below, you can explore the drug types and trial stages. Clicking on a drug will provide additional information and you can download an Infosheet if there is one available.
Further information can be found on our website under Clinical Trials and Novel Drugs.
Filter by drug type
25 Immunotherapy
4 Epigenetic Drug
3 Proteasome Inhibitor
6 Cell Signalling/Cycle
Filter by trial stage
Order by
Drug name
Drugs in Phase I
I
Drugs in Phase II
II
Drugs in Phase III
III
Available Drugs
A
Epigenetic Drug | Drugs in Phase II
What is it?
Tazemetostat is an methyltransferase inhibitor.
How does it work?
Tazemetostat works by blocking the action of EZH2 methyltransferase, which may stop cancer cells from growing. A methyltransferase is an enzyme that adds methyl groups to DNA, proteins or other molecules, which can allow cancer cells to multiply. By blocking EZH2 methyltransferase, myeloma cells cannot grow which leads to cell death.
Immunotherapy | Drugs in Phase III
What is it?
Linvoseltamab is a new type of immunotherapy called a bispecific antibody. It is currently being tested for the treatment of myeloma.
How does it work?
Linvoseltamab works by helping your T-cells (a type of immune cell) find and kill myeloma cells. It attaches a protein, called BCMA, found on the surface of myeloma cells and a protein found on the surface of T-cells called CD3, forming a link between myeloma cells and the T-cell.
Immunotherapy | Drugs in Phase II, Drugs in Phase I
What is it?
Belantamab is a new type of immunotherapy called a monoclonal antibody. It is currently being tested for the treatment of myeloma.
Belantamab is also one of two components used to create the antibody-drug conjugate known as belantamab mafodotin (Blenrep®). However, belantamab and belantamab mafodotin are different treatments, so their suitability and availability may vary.
How does it work?
Belantamab attached to a protein, found on the surface of myeloma cells, called BCMA. This flags the myeloma cell to your own immune cells, helping them to find and kill the myeloma cells.
Cell Signalling/Cycle | Drugs in Phase I
What is it?
ABBV-453 is s a pro-survival inhibitor. It is currently being tested for the treatment of relapsed and/or refractory myeloma.
How does it work?
ABBV-453 stops a protein called B-Cell lymphoma-2 (BCL-2) from working. BCL-2 has been shown to help myeloma cells survive and grow. It is found in higher amounts in myeloma cells than healthy cells. By stopping BCL-2, myeloma cells will die.
Immunotherapy | Drugs in Phase I
What is it?
ABBV-383 is a new type of immunotherapy called a bispecific antibody. It is currently being tested for the treatment of relapsed and/or refractory myeloma.
How does it work?
ABBV-383 works by helping your T-cells (a type of immune cell) find and kill myeloma cells. It attaches to a protein, called GPRC5D, found on the surface of myeloma cells and a protein found on the surface of T-cells called CD3, forming a link between myeloma cells and the T-cell.
Immunotherapy | Drugs in Phase II
What is it?
SAR445514 is a new type of immunotherapy called a trispecific antibody. It is currently being tested for the treatment of relapsed and/or refractory myeloma and relapsed and/or refractory AL amyloidosis.
How does it work?
SAR445514 works by helping your NK cells (a type of immune cell) find and kill myeloma cells or the abnormal plasma
cells which are responsible for producing amyloid protein in AL amyloidosis. It attaches a protein called BCMA, found on the surface of myeloma cells and on the surface of abnormal plasma cells in AL amyloidosis, as well as to two proteins found on the surface of NK cells, called CD16 and NKp46, forming a link between myeloma cells/abnormal plasma cells and the NK cell.Other | Drugs in Phase II
What is it?
BGB-11417 is a pro-survival inhibitor. It is currently being tested for the treatment of relapsed and/or refractory myeloma, particularly for myeloma patients with the t(11:14) genetic abnormality.
How does it work?
BGB-11417 stops a protein called B-Cell lymphoma-2 (BCL-2) from working. BCL-2 has been shown to help myeloma cells survive and grow. It is found in higher amounts in myeloma cells than healthy cells. By stopping BCL-2 myeloma cells will die.
Immunotherapy | Drugs in Phase III
What is it?
Talquetamab is a new type of immunotherapy called a bispecific antibody. It is currently being tested for the treatment of relapsed and/or refractory myeloma.
How does it work?
Talquetamab works by helping your T-cells (a type of immune cell) find and kill myeloma cells. It attaches a protein, called GPRC5D, found on the surface of myeloma cells and a protein found on the surface of T-cells called CD3, forming a link between myeloma cells and the T-cell.
Immunotherapy | Drugs in Phase I
What is it?
JNJ-79635322 is a new type of immunotherapy called a trispecific antibody. It is currently being tested for the treatment of relapsed and/or refractory myeloma.
How does it work?
JNJ-79635322 works by helping your T-cells (a type of immune cell) find and kill myeloma cells. It attaches to two proteins, called BCMA and CD38, found on the surface of myeloma cells and a protein found on the surface of T-cells called CD3, forming a link between myeloma cells and the T-cell.
Cell Signalling/Cycle | Drugs in Phase III, Drugs in Phase II
What is it?
Cobimetinib is a type of drug known as a cancer growth blocker. It is currently being tested for the treatment of myeloma patients with a specific genetic abnormality (BRAF V600E mutation) in a phase II/III clinical trial in the UK.
How does it work?
MEK proteins release signals that encourage cancer cells to grow and multiply out of control.
Cobimetinib targets these MEK proteins and slows down or stops cancer cells from developing.
Cell Signalling/Cycle | Drugs in Phase III
What is it?
Vemurafenib is a type of drug known as a cancer growth blocker. It is currently being tested for the treatment of myeloma patients with a specific genetic abnormality (BRAF V600E mutation) in a phase II/III clinical trial in the UK.
How does it work?
Sometimes in cancer cells, there is a change in the BRAF gene, which means the cells make too much BRAF protein. This protein makes the cancer cells grow and divide.
Vemurafenib works by targeting this protein and so slows down or stops cancer cells from developing.
Other | Drugs in Phase II, Drugs in Phase I
What is it?
Modakafusp Alfa is a new drug conjugate. It is currently being tested for the treatment of relapsed and/or refractory myeloma in clinical trials.
How does it work?
Modakafusp Alfa combines a drug with an antibody that specifically targets a protein highly expressed on myeloma cells, CD-38. The antibody delivers the drug directly to myeloma cells, not the surrounding healthy cells.
Immunotherapy | Drugs in Phase II
What is it?
PHE885 is a type of immunotherapy known as chimeric antigen receptor T-cell (CAR-T cell) therapy. It is currently being tested for the treatment of relapsed and/or refractory myeloma in clinical trials.
How does it work?
CAR-T cells are a new type of treatment that uses the body’s own immune system to kill myeloma cells. CAR-T cells are made by taking T-cells (a type of immune cell) from the patient and modifying them to recognise myeloma cells more easily. PHE885 has been modified to recognise a protein found on the surface of myeloma cells, BCMA (B cell maturation antigen). This means that PHE885 can find and kill myeloma cells.
Immunotherapy | Drugs in Phase I
What is it?
REGN5458 is a new type of immunotherapy called a bispecific antibody. It is currently being tested for the treatment of relapsed and/or refractory myeloma.
How does it work?
REGN5458 works by helping your T-cells (a type of immune cells) find and kill myeloma cells. It attaches a protein, called BCMA, found on the surface of myeloma cells and a protein found on the surface of T-cells called CD3, forming a link between myeloma cells and the T-cell.
Cell Signalling/Cycle | Drugs in Phase II
What is it?
DTP3 is a pro-survival inhibitor. It is currently being tested for the treatment of relapsed/refractory myeloma in a phase I/II clinical trial in the UK.
How does it work?
DTP3 stops two proteins called GADD45b and MKK7 from working properly. GADD45b and MKK7 are part of the cell signalling system, which controls cell growth and survival. This system is exploited by myeloma cells so they can keep growing and multiplying.
It is hoped by stopping GADD45b and MKK7 from working, the cell survival system will be disrupted, and myeloma cells will die.
Immunotherapy | Drugs in Phase I
What is it?
Cevostamab is a new type of immunotherapy called a bispecific antibody. It is currently being tested for the treatment of relapsed and/or refractory.
How does it work?
Cevostamab works by helping your T-cells (a type of immune cells) find and kill myeloma cells. It attaches a protein, called BCMA, found on the surface of myeloma cells and a protein found on the surface of T-cells called CD3, forming a link between myeloma cells and the T-cell.
Immunotherapy | Drugs in Phase I
What is it?
ANV-419 is an immunomodulatory drug. It is currently being tested for the treatment of relapsed/refractory myeloma in a Phase I/II clinical trial in the UK.
How does it work?
ANV-419 works by affecting the body’s immune system. It is hoped the drug will increase the production of immune cells that can kill cancer cells.
Immunotherapy | Available Drugs
What is it?
Elranatamab is a new type of immunotherapy called a bispecific antibody. It is currently being tested for the treatment of relapsed and/or refractory.
How does it work?
Elranatamab works by helping your T-cells (a type of immune cell) find and kill myeloma cells. It attaches a protein, called BCMA, found on the surface of myeloma cells and a protein found on the surface of T-cells called CD3, forming a link between myeloma cells and the T-cell.
Immunotherapy | Drugs in Phase I
What is it?
Forimtamig (RO7425781) is a new immunotherapy drug. It is currently being tested for the treatment of relapsed and refractory myeloma in a Phase I clinical trial in the UK.
How does it work?
It is designed to help the body kill cancer cells. It does this by activating the immune system, in particular, T cells (a type of immune cells) against cancer cells.
Immunotherapy | Drugs in Phase I
What is it?
CID-103 is a new monoclonal antibody. It is currently being tested for the treatment of relapsed and/or refractory myeloma.
How does it work?
CID-103 works by attaching to a protein found on the surface of myeloma cells, CD38. It attaches to CD38 making the myeloma cell more visible to the immune system. This allows the immune system to target and kill the myeloma cell.
Immunotherapy | Drugs in Phase III
What is it?
Teclistamab is a new type of immunotherapy called a bispecific antibody. It is currently being tested for the treatment of relapsed and/or refractory.
How does it work?
Teclistamab works by helping your T-cells (a type of immune cells) find and kill myeloma cells. It attaches a protein, called BCMA, found on the surface of myeloma cells and a protein found on the surface of T-cells called CD3, forming a link between myeloma cells and the T-cell.
Immunotherapy | Drugs in Phase III
What is it?
Cilta-cel is a type of immunotherapy known as chimeric antigen receptor T-cell (CAR-T cell) therapy. It is currently being tested for the treatment of relapsed and/or refractory myeloma.
How does it work?
CAR-T cells are a new type of treatment that uses the body’s own immune system to kill myeloma cells. CAR-T cells are made by taking T-cells (a type of immune cell) from the patient and modifying them to recognise myeloma cells more easily. Cilta-cel has been modified to recognise a protein found on the surface of myeloma cells, BCMA (B cell maturation antigen). This means that it can identify and kill myeloma cells.
Epigenetic Drug | Drugs in Phase I
What is it?
CCS1477 is a type of drug known as a bromodomain inhibitor. It is currently being tested for the treatment of relapsed/refractory myeloma in a phase I/II clinical trial in the UK.
How does it work?
CSS1477 works by blocking the cells ability to read and translate specific sections of DNA.
It is hoped this will stop myeloma cells from producing the proteins they depend on to keep growing and multiplying.Cell Signalling/Cycle | Drugs in Phase I
What is it?
S65487 is a pro-survival inhibitor. It has been tested for the treatment for myeloma in a phase I trial in the UK.
How does it work?
S65487 stops a protein called B-Cell lymphoma-2 (BCL-2) from working. BCL-2 has been shown to help myeloma cells survive and grow. It is found in higher amounts in myeloma cells than healthy cells. By stopping BCL-2 myeloma cells will die.
Other | Drugs in Phase I
What is it?
Uprolselan is a E-selectin inhibitor. It is being tested in combination with standard treatment for the treatment of myeloma.
How does it work?
Uprolselan is thought to improve the effectiveness of chemotherapy. It helps move myeloma cells from the bone marrow into the blood where they can be more easily killed by the chemotherapy. It does this by blocking a protein (E-selectin) which helps myeloma cells stick to bone marrow.
Immunotherapy | Drugs in Phase III
What is it?
Mezigdomide (CC-92480) is an immunomodulatory drug (IMiD). It is currently being tested for the treatment of relapsed/refractory myeloma in clinical trials in the UK.
How does it work?
Mezigdomide works by affecting the body’s immune system. It is thought to do this by stopping a protein called cereblon from working properly.
Immunotherapy | Drugs in Phase III
What is it?
CC-220 is an immunomodulatory drug (IMiD). It is currently being tested for the treatment of relapsed/refractory myeloma in clinical trials in the UK.
How does it work?
CC-220 works by affecting the body’s immune system. It is thought to do this by stopping a protein called cereblon from working properly.
Immunotherapy | Drugs in Phase III
What is it?
Idecabtagene vicleucel is a type of immunotherapy known as chimeric antigen receptor T-cell (CAR-T cell) therapy. It is currently being tested for the treatment of relapsed and/or refractory myeloma in a number of clinical trials.
How does it work?
CAR-T cells are a new type of treatment that uses the body’s own immune system to kill myeloma cells. CAR-T cells are made by taking T-cells (a type of immune cell) from the patient and modifying them to recognise myeloma cells more easily. Ide-cel has been modified to recognise a protein found on the surface of myeloma cells, BCMA (B cell maturation antigen). This means that ide-cel can find and kill myeloma cells.
Immunotherapy | Drugs in Phase III
What is it?
Belantamab mafodotin is a new type of immunotherapy called an antibody-drug conjugate. It has been approved for use in the US and Europe for the treatment of relapsed and/or refractory myeloma patients but it is not currently available through the NHS in the UK.
How does it work?
Belantamab mafodotin is a chemotherapy drug connected to an antibody. The antibody allows the drug to find and attach to a protein found on the surface of myeloma cells, BCMA (B cell maturation antigen). After it attaches to BCMA the chemotherapy drug separates from the antibody and kills the myeloma cell.
Other | Drugs in Phase I
What is it?
Reolysin® is an oncolytic virus. It is being tested in Phase I clinical trials for the treatment of relapsed/refractory myeloma.
How does it work?
Reolysin infects and kills myeloma cells. It also increases the immune response against the myeloma cells, so their action against the myeloma cells is increased.
Immunotherapy | Available Drugs
What is it?
Thalidomide is an immunomodulatory drug (IMiD). It is approved for the treatment myeloma patients.
How does it work?
Thalidomide works by affecting the body’s immune system. It helps to kill myeloma cells in a number of different ways.
Immunotherapy | Available Drugs
What is it?
Lenalidomide is an immunomodulatory drug (IMiD). It is approved for use, with restrictions, from first line.
How does it work?
Lenalidomide works by affecting the body’s immune system. It helps to kill myeloma cells in a number of different ways.
Other | Available Drugs
What is it?
Selinexor is a selective inhibitor of nuclear export (SINE). It has been approved for use in the US and Europe for the treatment of relapsed and/or refractory myeloma patients but it is not currently available through the NHS in the UK.
How does it work?
Selinexor stops a protein called Exportin 1 (XPO1) from working properly. XPO1 is a protein responsible for moving other proteins between different parts of the cell. Myeloma cells exploit XPO1 to get rid of proteins, called tumour suppressor proteins, which would stop them from growing and multiplying. By blocking XPO1, the tumour suppressor proteins build up killing myeloma cells.
Immunotherapy | Available Drugs
What is it?
Pomalidomide is an immunomodulatory drug (IMiD). It has been approved in combination with dexamethasone for myeloma patients from 3rd line.
How does it work?
Pomalidomide works by affecting the body’s immune system. It helps to kill myeloma cells in a number of different ways.
Other | Drugs in Phase III
What is it?
Venetoclax is a pro-survival inhibitor. It has been tested for the treatment for myeloma in a number of clinical trials, including trials in the UK. It is thought to be most effective in myeloma patients with the t(11:14) genetic abnormality.
How does it work?
Venetoclax stops a protein called B-Cell lymphoma-2 (BCL-2) from working. BCL-2 has been shown to help myeloma cells survive and grow. It is found in higher amounts in myeloma cells than healthy cells. By stopping BCL-2 myeloma cells will die.
Other | Available Drugs
What is it?
Dexamethasone is a steroid drug. It is approved for the treatment myeloma patients.
How does it work?
Dexamethasone mimics the action of a naturally occurring hormone produced in the body. It is effective at killing myeloma cells and making other anti-myeloma drugs work better. It can also prevent inflammation which can help to reduce pain associated with myeloma bone disease.
Other | Available Drugs
What is it?
Prednisolone is a steroid drug. It is approved for the treatment myeloma patients.
How does it work?
Prednisolone mimics the action of a naturally occurring hormone produced in the body. It is effective at killing myeloma cells and making other anti-myeloma drugs work better. It can also prevent inflammation which can help to reduce pain associated with myeloma bone disease.
Immunotherapy | Available Drugs
What is it?
Isatuximab is a next-generation monoclonal antibody. It is approved for use through the NHS at 4th line (third relapse).
How does it work?
It works by attaching to a protein found on the surface of myeloma cells, CD38. It has been shown to kill myeloma cells directly and to help the immune system to better target and kill myeloma cells.
Epigenetic Drug | Drugs in Phase II
What is it?
CHR3996 is a histone deacetylase (HDAC) inhibitor. It was tested for the treatment of relapsed/refractory myeloma in a phase I/II trial (MUK three).
How does it work?
CHR3996 works by blocking the action of a protein, called histone deacetylase (HDAC), in myeloma cells. HDAC is needed for cell growth. By stopping HDAC myeloma cells stop growing and multiplying.
Other | Drugs in Phase II
What is it?
Tosedostat is an aminopeptidase inhibitor. It has been tested for the treatment of relapsed/refractory myeloma.
How does it work?
Tosedostat works by blocking the action of aminopeptidases. Aminopeptidases are proteins which help cells get the building blocks (amino acids) they need to grow and multiply. By blocking aminopepitidases the myeloma cells cannot grow which leads to cell death.
Proteasome Inhibitor | Available Drugs
What is it?
Carfilzomib is a proteasome inhibitor. It is approved in combination with dexamethasone for the treatment of myeloma patients from 2nd line (first relapse). It is also approved in combination with lenalidomide (Revlimid) and dexamethasone for the treatment of myeloma patients at 2nd line (first relapse).
How does it work?
It works by blocking the actions of proteasomes. Proteasomes are large molecules found in all cells of the body, and they are involved in the breakdown of damaged or unwanted proteins. Carfilzomib permanently blocks their function, stopping them from breaking down unwanted proteins. This causes proteins to build up to toxic levels, killing the cell. Myeloma cells rely more heavily on proteasomes than normal healthy cells; they are therefore much more sensitive to carfilzomib.
Proteasome Inhibitor | Available Drugs
What is it?
Bortezomib is a proteasome inhibitor. It is approved for use for newly diagnosed and relapsed/refractory myeloma patients.
How does it work?
It works by blocking the actions of proteasomes. Proteasomes are large molecules found in all cells of the body, and they are involved in the breakdown of damaged or unwanted proteins. Bortezomib temporarily blocks their function, stopping them from breaking down unwanted proteins. This causes proteins to build up to toxic levels, killing the cell. Myeloma cells rely more heavily on proteasomes than normal healthy cells; they are therefore much more sensitive to bortezomib.
Chemotherapy | Available Drugs
What is it?
Cyclophosphamide is an alkylating chemotherapy drug. It is approved for the treatment of myeloma.
How does it work?
Cyclophosphamide works by damaging the DNA within myeloma cells. Damaging the DNA stops the myeloma cells multiplying and results in their death.
Chemotherapy | Available Drugs
What is it?
Melphalan is an alkylating chemotherapy drug. It is approved for the treatment of myeloma.
How does it work?
Melphalan works by damaging the DNA within myeloma cells. Damaging the DNA stops the myeloma cells multiplying and results in their death.
Chemotherapy | Available Drugs
What is it?
Etoposide is a chemotherapy drug. It is sometimes used to treat relapsed/refractory myeloma in a combination called DT-PACE.
How does it work?
Etoposide stops a protein called topoisomerase-2 from working properly. This slows or stops the growth of myeloma cells.
Chemotherapy | Available Drugs
What is it?
Cisplatin is a chemotherapy drug. It is sometimes used to treat relapsed/refractory myeloma in a combination called DT-PACE.
How does it work?
Cisplatin works by damaging the DNA within myeloma cells. Damaging the DNA stops the myeloma cells multiplying and results in their death.
Epigenetic Drug | Available Drugs
What is it?
Panobinostat is a histone deacetylase (HDAC) inhibitor. It is approved for use, with restrictions, from 3rd line.
How does it work?
Panobinostat works by blocking the action of a protein called histone deacetylase (HDAC) in myeloma cells. HDAC is needed for cell growth. By stopping HDAC, myeloma cells stop growing and multiplying.
Chemotherapy | Available Drugs
What is it?
Doxorubicin is a chemotherapy drug. It is sometimes used to treat relapsed/refractory myeloma in a combination called DT-PACE.
How does it work?
Doxorubicin stops a protein called topoisomerase-2 from working properly. This slows or stops the growth of myeloma cells.
Chemotherapy | Available Drugs
What is it?
Bendamustine is an alkylating chemotherapy drug. It is sometimes used for the treatment of relapsed/refractory myeloma.
How does it work?
Bendamustine works by damaging the DNA within myeloma cells. Damaging the DNA stops the myeloma cells multiplying and results in their death.
Immunotherapy | Drugs in Phase III
What is it?
Elotuzumab is a monoclonal antibody. It has been approved for use in the US and Europe in combination with lenalidomide (Revlimid) and dexamethasone but it is not currently available through the NHS in the UK.
How does it work?
It works by attaching to a protein found on the surface of myeloma cells, SLAM-7. Elotuzumab attaches to SLAM-7 making the myeloma cell more visible to the immune system. This allows the immune system to target and kill the myeloma cell.
Immunotherapy | Available Drugs
What is it?
Daratumumab is a monoclonal antibody. Daratumumab has been approved for use on the NHS for myeloma patients as a 4th line treatment and in combination with bortezomib (Velcade) and dexamethasone for myeloma patients as a 2nd line treatment. It is also available in combination with bortezomib, thalidomide and dexamethasone as induction treatment before high-dose therapy and stem cell transplantation.
How does it work?
It works by attaching to a protein found on the surface of myeloma cells, CD38. Daratumumab attaches to CD38 making the myeloma cell more visible to the immune system. This allows the immune system to target and kill the myeloma cell.
Proteasome Inhibitor | Available Drugs
What is it?
Ixazomib is an oral proteasome inhibitor. It is approved in combination with lenalidomide and dexamethasone as a 3rd or 4th line treatment for myeloma patients in England, Wales and Northern Ireland.
How does it work?
It works by blocking the actions of proteasomes. Proteasomes are large molecules found in all cells of the body, and they are involved in the breakdown of damaged or unwanted proteins. Ixazomib temporarily blocks their function, stopping them from breaking down unwanted proteins. This causes proteins to build up to toxic levels, killing the cell. Myeloma cells rely more heavily on proteasomes than normal healthy cells; they are therefore much more sensitive to ixazomib.
Other | Drugs in Phase III
What is it?
Melflufen is a derivative of melphalan, in which melphalan is bound to a peptide (small protein). Melflufen is being investigated for the treatment of relapsed and/or refractory myeloma patients.
How does it work?
Melflufen targets myeloma cells using peptidases (enzymes that break down peptides) which are often found at higher concentrations in myeloma cells. The peptidases in the myeloma cells break up melflufen releasing active melphalan. The melphalan can then kill the myeloma cell.
